Yehonatan Noyman

Dr. Yehonatan Noyman

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2021 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
HNHadas Prag Naveh
Hadas Prag Naveh
IAIris Amitay-Laish
Iris Amitay-Laish
OZOmri Zidan
Omri Zidan
YLYael A. Leshem
Yael A. Leshem
SSShany Sherman
Shany Sherman
EHEmmilia Hodak
Emmilia Hodak
Real-life efficacy data on the recently approved once daily application of chlormethine gel (CG) for mycosis fungoides (MF) is limited, and detailed characterization of the side effects and their m...

13 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MMMaya Engler Markowitz
Maya Engler Markowitz
YNYehonatan Noyman
Yehonatan Noyman
IKIsrael Khanimov
Israel Khanimov
IZItay Zahavi
Itay Zahavi
BDBatya Davidovici
Batya Davidovici
ALAssi Levi
Assi Levi
Background: Solar urticaria is a rare and disabling photodermatosis. Due to its low prevalence, most available data regarding treatment are derived from observational studies and case series, and a systematic evaluation of treatment efficacy is lacking. This systematic review and meta-analysis aims to assess therapeutic outcomes across treatment modalities in order to guide clinical care. Methods: We conducted a systematic literature search across PubMed, ScienceDirect, the Cochrane Library, and ClinicalTrials.gov. Studies reporting treatment outcomes in patients with solar urticaria were included. Pooled response rates were calculated for each treatment modality. Results: Out of 508 studies initially identified, 38 met the inclusion criteria. Antihistamines were evaluated in 21 studies (376 patients), with a pooled response rate (partial or complete) of 83.0% (95% CI, 70.4–91.1%) and a complete response rate of 7.7% (95% CI, 1.7–28.3%). Phototherapy was assessed in 11 studies (145 patients), showing a similar overall response (89.8%; 95% CI, 77.9–95.3%) but a higher complete response rate (39.8%; 95% CI, 18.3–66.1%). Omalizumab, evaluated in nine studies (76 patients), demonstrated the highest efficacy, with 93.2% (95% CI, 73.8–98.5%) achieving response and 68.4% (95% CI, 48.5–83.2%) complete remission. Limited data on IVIG, cyclosporine, and plasmapheresis suggested partial efficacy in selected refractory cases. Conclusions: This meta-analysis may support clinical decision-making by clinicians. A stepwise approach is suggested: high-dose H1 antihistamines as first-line therapy, phototherapy as an alternative option in patients with access to treatment centers, and omalizumab for those with insufficient response. In refractory cases, additional options might be considered.

25 October 2021 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
PDF file
YNYehonatan Noyman
Yehonatan Noyman
ALAssi Levi
Assi Levi
OROfer Reiter
Ofer Reiter
MLMoshe Lapidoth
Moshe Lapidoth

8 February 2021 in Photodermatology, Photoimmunology & Photomedicine
Verified
Journal Article
Open access
PDF file
YNYehonatan Noyman
Yehonatan Noyman
YEYonatan Edel
Yonatan Edel
ISIgor Snast
Igor Snast
SSShany Sherman
Shany Sherman
RKRan Kaftory
Ran Kaftory
ALAssi Levi
Assi Levi
Background Inherited genetic erythropoietic protoporphyria (EPP) is characterized by a photosensitive rash that emerges during infancy or early childhood. Acquired EPP can erupt at any age, even during adulthood, and is associated with hematological disorders. A third, less‐studied type of EPP is also inherited but appears later in life (during adulthood). Purpose To evaluate the characteristics of inherited genetic late‐onset (IGLO) EPP. Methods A systematic comprehensive search of the literature was conducted using PubMed, Google Scholar, ScienceDirect, and clinicaltrials.gov databases. Studies describing patients with IGLO EPP were included. Additionally, we present an index case of a patient, treated at our clinic in whom inherited genetic EPP was diagnosed at age 21 years. Results The search yielded 1514 citations. Five publications were eligible for review. Along with our case, 7 patients (4 males) were included in the analysis. Mean age at disease onset was 34.2 years (range 18‐69, median 30). Most patients presented with mild pruritus and rash in a photosensitive distribution. Mean level of free erythrocyte protoporphyrin IX (FEP) was 8.6 μmol/L. A mutant ferrochelatase gene (FECH) in trans to a hypomorphic FECH allele was found in 3 of the 4 patients who underwent genetic testing. Conclusion We describe the distinct features of IGLO EPP. This work emphasizes that a diagnosis of inherited genetic EPP should not be ruled out in adults with new‐onset photosensitive manifestations.

18 November 2024 in Journal of Burn Care & Research
Verified
Journal Article
Closed access
PDF file
DYDafna Shilo Yaacobi
Dafna Shilo Yaacobi
YHYehiel Hayun
Yehiel Hayun
DHDaniel Hilewitz
Daniel Hilewitz
DADean D Ad-El
Dean D Ad-El
SMSagit Meshulam-Derazon
Sagit Meshulam-Derazon
AOAsaf Olshinka
Asaf Olshinka
The Swords of Iron (SOI) War is an armed conflict between Israel and Hamas, which has been taking place in Gaza from October 2023 until the present time of writing this article. This war is characterized by urban close contact combat. The combat equipment, weaponry, and protective measures employed, differ markedly from those in previously documented major conflicts, significantly impacting the types of injuries sustained by soldiers. This study examines the number of injured soldiers in combat, field mortality rates, incidence of burns and trauma, demographic details of the injured, causes and distribution of injuries, burn characteristics, hemodynamic status, and injury severity. This is a retrospective, registry-based cohort study. Military personnel treated by IDF medical teams with burn injuries from the ground maneuver in Gaza between October 27th, 2023 to April 2024 were included in the analysis. Diagnosis of burn injuries was made in the prehospital setting and recorded in the patient’s casualty cards and the IDF trauma registry and/or in the hospitals, and then recorded by the Israel National Trauma Registry. A total of 2,627 documented military personnel were included. Of them, there was a total of 249 burn casualties. They were all male combat soldiers and their mean age was 22 years. Most of the burn injuries were combined with other injuries, only 12% were defined as in shock state, and 14% received whole blood in the field. The burn degree was second and third degree for most cases. A third (34%) of burn injured soldiers had surgery (Table 2), and half of the total were sent to rehabilitation departments following their initial hospitalization. An analysis of total body surface area (TBSA)% affected by burns among SOI War casualties reveals a higher proportion of severe burns exceeding 20% TBSA, compared to previous conflicts. Additionally, a higher proportion of personnel suffered from second and third degree burns. This is likely attributed to the operational mode of the IDF in Gaza, where urban close-contact warfare exposes soldiers to heightened risks of explosive and blast injuries. A significant percentage of live casualties had TBSA percentages that were not life-threatening, which underscores the importance of updating emergency burn treatment protocols and employing rapid evacuation and medical response systems in the field. Most of the wounded that suffer from significant burns had other significant and life-threatening injuries, making the appropriate protective measures and the preparation for rapid evacuation the best way to improve burn casualty survival. The significance of this research lies in the timely analysis of accumulated combat data to derive lessons and conclusions relevant to ongoing and future conflicts, and to understand the clinical implications arising from combat situations. Given the relatively high prevalence of burn injuries, understanding their etiology, severity, and consequences is essential for developing effective prevention and treatment courses.

9 June 2025 in Lasers in Medical Science
Verified
Journal Article
Open access
PDF file
YNYehonatan Noyman
Yehonatan Noyman
HFHadas Ofer Friedman
Hadas Ofer Friedman
MLMoshe Lapidoth
Moshe Lapidoth
GRGaia Harris Rimon
Gaia Harris Rimon
ESEfrat Solomon-Cohen
Efrat Solomon-Cohen
ALAssi Levi
Assi Levi
Purpose: Phymatous rosacea is a chronic and disfiguring subtype of rosacea, mainly affecting the nose and leading to the development of rhinophyma. This condition manifests with erythema, enlarged pores and increased sebum secretion, progressing to textural alterations and nasal hypertrophy. Ablative CO 2 laser resurfacing has emerged as a preferred approach, offering hemostatic control and favorable cosmetic outcomes. This case series presents our treatment experience with a non-fractional ablative CO 2 laser resurfacing under local anesthesia for severe rhinophyma patients. Methods: A Retrospective case series of patients with severe rhinophyma treated with an ablative CO 2 laser between December 2010 and March 2020 in our laser unit. Post-procedure aesthetic outcome was assessed by the treating physician 3 months following treatment and patients were asked to complete a long-term follow-up questionnaire. Results: Sixteen patients (15 males) were included, of which 13 patients (81%) had completed the questionnaire on an average of 15 months following treatment (range 2–24 months). Patient satisfaction following treatment was high, with an average satisfaction score of 7.9 out of 10 (range 4–10). Post-procedure aesthetic outcome was rated as very good or excellent in 13 patients (81%, with 75% or greater improvement). Among the 13 patients who completed the questionnaire, 11 (85%) indicated that they would recommend this treatment to others with a similar condition. Conclusion: Non-fractional, ablative CO 2 laser resurfacing performed under local anesthesia, has proven to be a safe, effective and well-tolerated treatment for severe rhinophyma, yielding sustainable results and high satisfaction rate.